Met Life Investment Management, LLC Phathom Pharmaceuticals, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 24,366 shares of PHAT stock, worth $138,155. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,366
Previous 19,029
28.05%
Holding current value
$138,155
Previous $344,000
42.73%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding PHAT
# of Institutions
158Shares Held
68.6MCall Options Held
52.3KPut Options Held
635K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$57.3 Million4.92% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$42.3 Million13.31% of portfolio
-
Jennison Associates LLC7.06MShares$40 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA3.67MShares$20.8 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$19.8 Million28.4% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $222M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...